Lawsuit probes ClearPoint Neuro over stock drop after Huntington's drug trial setback

Pomerantz LLP is investigating ClearPoint Neuro and its executives for possible securities fraud following a significant stock price drop. The decline occurred after ClearPoint's partner, uniQure, announced that their Huntington's disease treatment failed to meet key clinical goals. The stock fell 23.12% on the news, prompting the class action inquiry. Investors affected by the drop are encouraged to contact Pomerantz LLP for potential legal action.

ClearPoint Neuro (CLPT) trades at USD 9.50 on Pluang, showing a 5.09% gain as of Oct 28, 2026 05:02 WIB, despite the recent sharp stock drop reported in the news. The stock's market cap stands at $275.45 million with a 52-week low of $8.66 and a high of $26.98. Pluang investors currently hold the stock for an average of 11 days, with all recent orders being buys, highlighting continued interest amid the legal investigation.